AstraZeneca's Tagrisso shows 47% death risk reduction at eight years

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to AstraZeneca's Tagrisso shows 47% death risk reduction at eight years

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

September 13, 2026 9:47 PM EDT

Longest survival data ever reported in a global Phase III trial in this setting

New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages

WILMINGTON, Del.--(BUSINESS WIRE)-- Updated exploratory results from the ADAURA Phase III trial showed AstraZenecas TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer... More